A compound according to formula (i), wherein W is selected from a C-Sp2-Sp2-C bond, O, SO 2, S, N Z is selected from C or N, Z' is selected from C, or N, Y' is selected from C or N, Y is selected from C or N, R1 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Ak, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, or amide, R2 denotes H, halogen, CF 3, OMe, Alkoxy, Alk, S-Ak, SMe, SO 2 Me, SO 2 Alkyl, NO 2, keto, amino, or amide, R3 denotes H, halogen, CF 3, OMe, SO 2, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, or amide, R4 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk,, NO 2, keto, amino, or amide, R5 denotes H, alkyl, benzyl, amide, sulfonamide, Alk, Alkoxy, NO 2, alkoxy, OMe, NO 2, keto, amino, or amide, R6 denotes H, alkyl, OMe, SO 2, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, or amide, R7 denotes H, halogen, SO 2, SO 2 Alk, or S-Alk, Alk, Alkoxy, keto, amino, or amide, R8 denotes H, halogen, CF3, alk, alkoxy, keto, amino, amide, SO 2, S-Alk, R9 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, amide, azepanyl, azepanyl-3-ol, or amino-azepanyl-3-ol R10 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, aryl, hydroxyl, amino, or amide, and Alk is a branched or linear alkyl group having 1 to 8 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, wherein 1 to 7 H-atoms may be independently replaced by Hal, OR, COOR, CN, NR 2, phenyl, linear or branched alkyl having 1, 2 or 3 C atoms, cycloalkyl having 3 to 6 carbon atoms and/or wherein 1 to 3 CH 2 -groups may be replaced by O, -NRCO-, -CO-, -COO-, -CONR, -NR- or S, or cycloalkyl having 3 to 6 carbon atoms, and the pharmaceutically acceptable salts, esters and N-oxides thereof, in a racemic form or in an enantiomerically pure form or enriched mixture of the respective enantiomers in all ratios, and/or as a mixture of diastereoisomers in all ratios. W is selected from a C-Sp2-Sp2-C bond, O, SO 2, S, N Z is selected from C or N, Z' is selected from C, or N, Y' is selected from C or N, Y is selected from C or N, R1 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Ak, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, or amide, R2 denotes H, halogen, CF 3, OMe, Alkoxy, Alk, S-Ak, SMe, SO 2 Me, SO 2 Alkyl, NO 2, keto, amino, or amide, R3 denotes H, halogen, CF 3, OMe, SO 2, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, or amide, R4 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk,, NO 2, keto, amino, or amide, R5 denotes H, alkyl, benzyl, amide, sulfonamide, Alk, Alkoxy, NO 2, alkoxy, OMe, NO 2, keto, amino, or amide, R6 denotes H, alkyl, OMe, SO 2, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, or amide, R7 denotes H, halogen, SO 2, SO 2 Alk, or S-Alk, Alk, Alkoxy, keto, amino, or amide, R8 denotes H, halogen, CF3, alk, alkoxy, keto, amino, amide, SO 2, S-Alk, R9 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, amino, amide, azepanyl, azepanyl-3-ol, or amino-azepanyl-3-ol R10 denotes H, halogen, CF 3, OMe, Alk, Alkoxy, S-Alkyl, SMe, SO 2 Me, SO 2 Alk, NO 2, keto, aryl, hydroxyl, amino, or amide, and Alk is a branched or linear alkyl group having 1 to 8 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, wherein 1 to 7 H-atoms may be independently replaced by Hal, OR, COOR, CN, NR 2, phenyl, linear or branched alkyl having 1, 2 or 3 C atoms, cycloalkyl having 3 to 6 carbon atoms and/or wherein 1 to 3 CH 2 -groups may be replaced by O, -NRCO-, -CO-, -COO-, -CONR, -NR- or S, or cycloalkyl having 3 to 6 carbon atoms, and the pharmaceutically acceptable salts, esters and N-oxides thereof, in a racemic form or in an enantiomerically pure form or enriched mixture of the respective enantiomers in all ratios, and/or as a mixture of diastereoisomers in all ratios.